CTOs on the Move

Freenome

www.freenome.com

 
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.freenome.com
  • 259 East Grand Avenue Suite 3434
    South San Francisco, CA USA 94080
  • Phone: 831.704.6883

Executives

Name Title Contact Details

Funding

Freenome raised $65M on 03/01/2017
Freenome raised $160M on 07/24/2019
Freenome raised $270M on 08/26/2020

Similar Companies

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutrawise Corp

Nutrawise Corp is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Demetrix

Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.

CombiMatrix Corporation

CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caribou Biosciences

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.